By Rob Curran

Shares of life-sciences firm Avantor slid premarket after the company logged lower fourth-quarter net income and sales, and said 2026 would mark a transitional phase of a long-term turnaround plan.

The Radnor, Pa., provider of specialized chemicals and equipment to laboratories, posted earnings of $52.4 million, or 8 cents a share, down sharply from $500.4 million, or 73 cents a share, a year earlier. Analysts, on average, had anticipated earnings of 12 cents a share.

Stripping out certain one-off items, Avantor posted adjusted earnings of 22 cents a share, in line with the average Wall Street peg, as per FactSet.

Sales fell 1% to $1.66 billion.

Shares slid 11% to $9.88 premarket.

Avantor has recently launched a turnaround plan, dubbed Revival.

"We are moving with urgency to execute Revival and turn around the performance of this great business," said President and Chief Executive Emmanuel Ligner, in a statement. "2026 will be a year of transition and purposeful investment, and our priority is driving top line growth by competing vigorously in the marketplace and strengthening our company."

Shares had taken a beating in November after Avantor posted a third-quarter loss due to a charge.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

February 11, 2026 08:07 ET (13:07 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.